The study was conducted to provide insight into real-world Bruton tyrosine kinase (BTK) inhibitor treatment patterns in mantle cell lymphoma, as current data are limited. A real-world analysis of ...
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...
In patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intolerant to ibrutinib or acalabrutinib, zanubrutinib demonstrated favorable tolerability with only 40% of ibrutinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results